| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/17/2006 | US20060182745 Tetraspanin specific immunoglobulin for use in treatment and prevention of allergic disorders; immunotherapy |
| 08/17/2006 | US20060182744 Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| 08/17/2006 | US20060182743 Methods of treating skin disorders using an IL-31RA antagonist |
| 08/17/2006 | US20060182742 System and method for magnifying a humoral immune response |
| 08/17/2006 | US20060182741 Use of adcc-optimized antibodies for treating weak patients |
| 08/17/2006 | US20060182740 Buffered formulations for concentrating antibodies and methods of use thereof |
| 08/17/2006 | US20060182739 By ion exchange chromatography and involves changing the conductivity and/or pH of buffers in order to resolve the polypeptide of interest |
| 08/17/2006 | US20060182738 Medical device for analyte monitoring and drug delivery |
| 08/17/2006 | US20060182730 Antiobesity agent using hen's egg antibody against digestive enzymes |
| 08/17/2006 | US20060182726 Immunomodulating compositions, processes for their production and uses therefor |
| 08/17/2006 | US20060182715 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss |
| 08/17/2006 | US20060182714 Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| 08/17/2006 | US20060182713 Vaccine composition comprising interleukin-15 (il-15) |
| 08/17/2006 | US20060182684 non-invasive and flexible method and carrier for drug delivery across the blood-brain barrier; brain tumors, brain metastases, stroke, schizophrenia, epilepsy, Alzheimer's, Parkinson's and Huntington's disease |
| 08/17/2006 | US20060182683 Methods for reduced renal uptake of protein conjugates |
| 08/17/2006 | CA2597751A1 New detoxification method |
| 08/17/2006 | CA2597583A1 Support for protein transfer, protein transfer agent using the support, protein transfer method, cell having protein transferred thereinto and method of producing the same |
| 08/17/2006 | CA2597512A1 Means for obtaining avirulent leishmania promastigotes, promastigotes obtained, and the applications thereof |
| 08/17/2006 | CA2597489A1 Surface-located streptococcus pneumoniae polypeptides |
| 08/17/2006 | CA2597265A1 Anti-interferon alpha monoclonal antibodies and methods for use |
| 08/17/2006 | CA2597098A1 Antibodies to tgfbeta |
| 08/17/2006 | CA2597059A1 Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells |
| 08/17/2006 | CA2596621A1 Site-specific immunization in order to establish antibodies with specificity for the e7 oncoprotein of high-risk hpvs |
| 08/17/2006 | CA2595960A1 Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs |
| 08/17/2006 | CA2595780A1 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus |
| 08/17/2006 | CA2595395A1 Inhibiting her2 shedding with matrix metalloprotease antagonists |
| 08/17/2006 | CA2572289A1 Anti-mcp-1 antibodies, compositions, methods and uses |
| 08/17/2006 | CA2570373A1 Il-13 binding agents |
| 08/16/2006 | EP1691197A2 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha |
| 08/16/2006 | EP1690941A1 Papilloma virus capsomere vaccine formulations and methods of use |
| 08/16/2006 | EP1690940A1 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 08/16/2006 | EP1690937A1 Method of constructing transgenic dendritic cell |
| 08/16/2006 | EP1690935A2 Generation of xenogeneic antibodies |
| 08/16/2006 | EP1690934A2 Generation of xenogeneic antibodies |
| 08/16/2006 | EP1690931A1 Live organism product |
| 08/16/2006 | EP1690875A1 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype |
| 08/16/2006 | EP1690868A1 Modification of virus tropism and host range by viral genome shuffling |
| 08/16/2006 | EP1690550A1 Therapeutic agent for mesothelioma |
| 08/16/2006 | EP1690549A1 Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals |
| 08/16/2006 | EP1690547A1 Prevention and treatment of amyloidogenic disease |
| 08/16/2006 | EP1690098A2 Biological materials and uses thereof |
| 08/16/2006 | EP1689872A1 Promoters for expression in modified vaccinia virus ankara |
| 08/16/2006 | EP1689867A1 Immunization against chlamydia infection |
| 08/16/2006 | EP1689866A2 Msp-3-like family of genes |
| 08/16/2006 | EP1689850A2 Inhibition of retroviral replication through modulation of the host cell ubiquitylation |
| 08/16/2006 | EP1689785A2 Use of metallic cations to improve functional activity of antibodies |
| 08/16/2006 | EP1689783A2 Mutated anti-cd22 antibodies and immunoconjugates |
| 08/16/2006 | EP1689782A1 Anti-igfr1 antibody therapeutic combinations |
| 08/16/2006 | EP1689781A2 Antibodies to cd44 glycoforms and uses thereof |
| 08/16/2006 | EP1689780A2 Tissue repair by modulation of beta-1 integrin biological function |
| 08/16/2006 | EP1689772A2 Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| 08/16/2006 | EP1689758A2 New class of gamma delta t cells activators and use thereof |
| 08/16/2006 | EP1689435A1 Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
| 08/16/2006 | EP1689434A1 The use of anti biotics as vaccine adjuvants |
| 08/16/2006 | EP1689433A1 Compositions and methods for activating innate and allergic immunity |
| 08/16/2006 | EP1689432A2 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 08/16/2006 | EP1689431A1 Cytoprotective effects of ethyl pyruvate |
| 08/16/2006 | EP1689430A2 Tyrosinase mutant and methods of use thereof |
| 08/16/2006 | EP1689418A1 Use of strain of bacillus and byproducts thereof for inhibiting formation of blood vessels |
| 08/16/2006 | EP1689361A2 Therapeutic combinations and methods including irm compounds |
| 08/16/2006 | EP1689347A2 Methods and reagents for treating, preventing and diagnosing bunyavirus infection |
| 08/16/2006 | EP1689346A2 Epha2 agonistic monoclonal antibodies and methods of use thereof |
| 08/16/2006 | EP1399476B1 Use of soluble cytokeratine-1-fragments in diagnostics |
| 08/16/2006 | EP1397488B1 Novel compounds for chemiluminescense procedures |
| 08/16/2006 | EP1363930B1 A method for generating genetically altered antigens |
| 08/16/2006 | EP1297013B1 Use of taci as an anti-tumor agent |
| 08/16/2006 | EP1292687B1 Regulated antigen delivery system (rads) involving bacteria |
| 08/16/2006 | EP1276853B1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 08/16/2006 | EP1268530B1 Hepatitis b core antigen fusion proteins |
| 08/16/2006 | EP1252192B1 Enhancing the circulating half-life of antibody-based fusion proteins |
| 08/16/2006 | EP1220908B1 Isolated peptides which bind to mhc class ii molecules, and uses thereof |
| 08/16/2006 | EP1186301B1 Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations |
| 08/16/2006 | EP1117682B1 Chi-Conotoxin Peptides as INhibitors of Neuronal Amine Transporters |
| 08/16/2006 | EP1087941B1 Thiolesters and uses thereof |
| 08/16/2006 | EP1058726B1 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines |
| 08/16/2006 | EP0972519B1 Immune tolerance inducers |
| 08/16/2006 | EP0827509B1 Modulation of cholesteryl ester transfer protein (cetp) activity |
| 08/16/2006 | CN1820200A Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 08/16/2006 | CN1820080A Product quality enhancement in mammalian cell culture processes for protein production |
| 08/16/2006 | CN1820078A Recombinant mutants of rhabdovirus and methods of use thereof |
| 08/16/2006 | CN1820075A Hepatitis B surface antigen blending gene and protein for carboxyl terminal containing precursor 32 immune decision cluster |
| 08/16/2006 | CN1820023A Recombinant expression of streptococcus pyogenes cysteine protease and immunogenic compositions thereof |
| 08/16/2006 | CN1820020A SARS-coronavirus virus-like particles and methods of use |
| 08/16/2006 | CN1819844A Immunogene adherence and method of making and using the same |
| 08/16/2006 | CN1819843A Method of enhanced immunogenicity to meningococcal vaccination |
| 08/16/2006 | CN1819842A Treating effect of using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 08/16/2006 | CN1819841A Methods of enhancing immune induction involving mda-7 |
| 08/16/2006 | CN1818053A Live organism product |
| 08/16/2006 | CN1817908A Recombinant solvent protein derivative, its production and use |
| 08/16/2006 | CN1817906A Antibody against human parathormone related peptides |
| 08/16/2006 | CN1817368A Vaccine for reticuloendothliosis of poultry and preparing method thereof |
| 08/16/2006 | CN1817367A Activation and inhibition of the immune system |
| 08/16/2006 | CN1269839C Treatment with anti-ErbB2 antibodies |
| 08/16/2006 | CN1269528C Application of dipeptide base peptidase IV effector for reducing blood sugar level of mammal |
| 08/16/2006 | CN1269524C Thymosin augmentation of genetic immunization |
| 08/16/2006 | CN1269477C Inflammation-inhibiting compounds |
| 08/15/2006 | USRE39240 pure peptides which are highly selective for a specific human receptor; treatment of neuromuscular disorders, rapid reversible immobilization of muscles in vertebrate species; pesticide |
| 08/15/2006 | US7091325 Fibrin/fibrinogen-binding conjugate |
| 08/15/2006 | US7091324 For diagnosis and therapy of HCV infection, including being useful in the identification of patients expected to benefit from certain therapeutic strategies |
| 08/15/2006 | US7091323 Human TIMP-1 antibodies |